A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer,
including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe
GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.